NASDAQ:SYNH - Syneos Health Stock Price, Forecast & News

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health Inc (NASDAQ:SYNH) announced its earnings results on Thursday, February, 20th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.01 by $0.02. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. Syneos Health had a return on equity of 10.12% and a net margin of 2.81%. The company's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.95 earnings per share. View Syneos Health's Earnings History.

Syneos Health is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Syneos Health.

Syneos Health issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $3.58-3.78 for the period, compared to the Thomson Reuters consensus estimate of $3.65. The company issued revenue guidance of $4.88-5.00 billion, compared to the consensus revenue estimate of $4.94 billion.

11 brokers have issued 1 year price objectives for Syneos Health's stock. Their forecasts range from $48.00 to $82.00. On average, they expect Syneos Health's share price to reach $69.11 in the next twelve months. This suggests that the stock has a possible downside of 2.4%. View Analyst Price Targets for Syneos Health.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.

Media stories about SYNH stock have been trending negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syneos Health earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Syneos Health.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), STARPHARMA HOLD/S (SPHRY) and Auxly Cannabis Group (CBWTF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include AT&T (T), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Icon (ICLR), Jazz Pharmaceuticals (JAZZ), Netflix (NFLX), Skyworks Solutions (SWKS), Alibaba Group (BABA) and Iqvia (IQV).

Syneos Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (2.23%), State Street Corp (1.92%), Bank of New York Mellon Corp (1.51%), Goldman Sachs Group Inc. (1.44%), Boston Partners (1.25%) and GW&K Investment Management LLC (1.05%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Principal Financial Group Inc., Prudential Financial Inc., Sei Investments Co., AXA, Goldman Sachs Group Inc., Boston Partners and Rothschild & Co. Asset Management US Inc.. View Insider Buying and Selling for Syneos Health.

SYNH stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jennison Associates LLC, Hennessy Advisors Inc., Barclays PLC, Knights of Columbus Asset Advisors LLC, Hawk Ridge Capital Management LP, ArrowMark Colorado Holdings LLC and Magnetar Financial LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $70.82.

Syneos Health has a market capitalization of $7.35 billion and generates $4.68 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.View Additional Information About Syneos Health.

The official website for Syneos Health is http://www.syneoshealth.com/.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]